Organisation paid for research Program year 2025 Source: CMS Open Payments

Wake Forest Baptist Hosp

Neither a doctor nor a teaching hospital

Research payments

$229,983

128 payments

Through program year 2025, Wake Forest Baptist Hosp is reported as receiving $229,983 in research payments, across 128 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$34,983	15
2024	Research	$129,456	40
2023	Research	$1,046	21
2022	Research	$19,417	28
2020	Research	$41,066	16
2019	Research	$4,014	8

Breakdown

Who paid Research payments · program years 2019–2025

Incyte Corporation $229,983 128 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms $101,818 35 payments
A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms $34,864 12 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis $27,745 6 payments
A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First Line Acute Graft Versus Host Disease $27,385 5 payments
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) $19,417 28 payments
A Phase 1, Double Blind, Randomized, Placebo Controlled, Multiple Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of INCB054707 When Administered Orally to Healthy Adult Volunteers $13,755 13 payments
A Phase 12, Open Label, Dose EscalationDose Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies $3,940 6 payments
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) $939 20 payments
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease $119 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.